Exome and genome test revenue grew to $98.9 million ... Expanded leadership in genomic newborn screening through ...

GeneDx is set for strong Q3 growth with rising exome and genome testing volumes and improving reimbursement trends. Learn why ...

The firm posted 2 percent overall revenue growth as strength in Europe and the Americas was offset by softness in China and the rest of Asia.

Could placental insufficiency be the hidden cause of stillbirths and childhood stunting? This article explores groundbreaking ...

A ground-breaking research study to help identify and treat rare genetic conditions in newborn babies has reached a major milestone with the recruitment of its 1,000th baby at Manchester ...

Revvity Inc (RVTY) reports robust Q3 performance with notable gains in software growth and strategic financial maneuvers, ...

For average-risk patients, screening mammography should begin at age 40. Patients who have an elevated risk of developing ...

Authors Table of Contents Media Contact For general and media inquiries and to book our experts, please contact: [email protected] For decades, the justice system has failed to recognize how deeply ...

Natera Inc. (($NTRA)) announced an update on their ongoing clinical study. Study Overview: Natera Inc. is conducting a study titled ‘EXpanding ...